Sulbactam enhances the in vitro activity of sitafloxacin against extensively-drug resistant Acinetobacter baumannii

Experimental and Therapeutic Medicine
Nannan XuQuantai Xing

Abstract

The present study aimed to determine the in vitro activities of sulbactam and sitafloxacin against extensively-drug resistant Acinetobacter baumannii (XDR-A. baumannii). A total of 50 strains of XDR-A. baumannii were isolated from clinical specimens. Broth microdilution assay was applied to determine the minimum inhibitory concentration (MIC) for sulbactam and sitafloxacin. Microdilution checkerboard method was used to determine the in vitro activity of this antimicrobial combination. Accordingly, the fractional inhibitory concentration (FIC) and FIC index (FICI) were calculated. Time-kill study was also carried out for four strains with different susceptibilities to determine the bactericidal activities of individual or combined use of sitafloxacin and sulbactam. Isolates with MICs of sitafloxacin ≤2 mg/l were considered to be susceptible to sitafloxacin. The susceptibility rate for sitafloxacin was 92% originally. When combined with sulbactam, this rate increased to 96%. Microdilution checkerboard results indicated that, when tested in combination, sulbactam/sitafloxacin exhibited marked synergistic and partial synergistic effects on 16 and 50% of the 50 strains, respectively. Time-kill assay suggested that sulbactam enhanced...Continue Reading

References

Jun 14, 2003·The Journal of Antimicrobial Chemotherapy·F C Odds
Aug 29, 2007·Drugs·Petros I RafailidisMatthew E Falagas
Nov 17, 2007·Nature Reviews. Microbiology·Lenie DijkshoornHarald Seifert
Mar 21, 2008·The New England Journal of Medicine·L Silvia Munoz-Price, Robert A Weinstein
Jul 16, 2008·Clinical Microbiology Reviews·Anton Y PelegDavid L Paterson
Apr 21, 2011·Drugs·Gillian M Keating
Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
Sep 17, 2011·American Journal of Respiratory and Critical Care Medicine·Doo Ryeon ChungUNKNOWN Asian Network for Surveillance of Resistant Pathogens Study Group
Oct 13, 2011·IUBMB Life·Gustavo M Cerqueira, Anton Y Peleg
Oct 27, 2011·Yonsei Medical Journal·Kyungwon LeeYunsop Chong
Feb 14, 2012·American Journal of Infection Control·Ryad DjeribiBouzid Menaa
Jun 27, 2012·Antimicrobial Agents and Chemotherapy·Sunil D SarojPhilip N Rather
Jul 24, 2013·International Journal of Antimicrobial Agents·Visanu Thamlikitkul, Surapee Tiengrim
Mar 26, 2014·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Yu-Shan HuangShan-Chwen Chang
May 17, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P PoulikakosM E Falagas
May 17, 2014·The Journal of Antimicrobial Chemotherapy·Stephan GöttigVolkhard A J Kempf
Jan 7, 2015·Antimicrobial Agents and Chemotherapy·William F PenwellAlita A Miller
Feb 3, 2015·Seminars in Respiratory and Critical Care Medicine·Yohei DoiAnton Y Peleg
Apr 11, 2015·International Journal of Antimicrobial Agents·Anaïs PotronPatrice Nordmann
Sep 16, 2017·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Paweł KrzyściakJadwiga Wójkowska-Mach

❮ Previous
Next ❯

Software Mentioned

Excel
VITEK

Related Concepts

Related Feeds

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.